Receptor News and Research

RSS

Enzalutamide shows promise in treating triple-negative and estrogen-positive breast cancer

Breast cancers are defined by their drivers - estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer treatment options - this aggressive form of breast cancer without ER, PR or HER2, which was thought not to be driven by hormones, is known as triple negative.

3 Dec 2012

Vitamin D receptor polymorphism may protect against osteoporosis

A polymorphism in the vitamin D receptor gene significantly influences risk for osteoporosis, suggest results from a meta-analysis of 26 studies.

3 Dec 2012

Tissue damage, disease severity in C. diff. infection associated with disruption of PPARγ pathway

Researchers in the Nutritional Immunology and Molecular Medicine Laboratory at Virginia Bioinformatics Institute have discovered how a common diarrhea-causing bacterium sends the body's natural defenses into overdrive, actually intensifying illness while fighting infection.

1 Dec 2012

Study of hospital-acquired infection yields potential therapeutic target

30 Nov 2012

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

Fn14 gene plays a role in growth and spread of non-small cell lung cancer tumors

Lung cancer researchers at St. Joseph's Hospital and Medical Center in Phoenix, Ariz., in collaboration with researchers at the Translational Genomics Research Institute and other institutions, have identified a gene that plays a role in the growth and spread of non-small cell lung cancer tumors, opening the door for potential new treatment options.

30 Nov 2012

Modified vitamin D receptor may reduce risk of osteoporosis

Osteoporosis, or reduced bone mineral density that can increase the risk of fractures, may affect as many as 30% of women and 12% of men worldwide. One risk factor for osteoporosis is vitamin D deficiency.

30 Nov 2012

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).

30 Nov 2012

LP-211 compound shows promise against Fragile X syndrome

A potential new therapeutic strategy for treating Fragile X syndrome is detailed in a new report appearing in the current issue of Biological Psychiatry, from researchers led by Dr. Lucia Ciranna at University of Catania in Italy.

29 Nov 2012

Study identifies metabolic factors related to bread's beneficial effects on cardiovascular health

According to a study, daily bread consumption, especially wholemeal bread, can prevent cardiovascular disease. The study has been led by the professor Rafael Llorach, Ramon y Cajal researcher from the Department of Nutrition and Bromatology at the Faculty of Pharmacy and from the Food and Nutrition Torribera campus of the University of Barcelona.

29 Nov 2012

IL17RC-mediated immune responses can be crucial in causing AMD

Changes in how genes in the immune system function may result in age-related macular degeneration (AMD), the leading cause of visual impairment in older adults, based on preliminary research conducted by National Institutes of Health (NIH) investigators.

29 Nov 2012

$ACE-inhibitors, angiotensin receptor blockers can treat heart failure with preserved ejection fraction$

ACE-inhibitors, angiotensin receptor blockers can treat heart failure with preserved ejection fraction

A novel study from Karolinska Institutet in Sweden suggests that commonly used drugs to treat heart failure and high blood pressure may have a wider range of application than earlier known, and also can be used against so called HFPEF - a type of heart failure that until now has been impossible to treat.

29 Nov 2012

NovImmune commences NI-0101 Phase I clinical trial in arthritis

NovImmune SA initiated dosing in a Phase I clinical trial of NI-0101, a monoclonal antibody drug candidate targeting toll-like receptor-4 (TLR4).

29 Nov 2012

High-resolution real-time images show how nerves may be damaged during earliest stages of MS

High-resolution real-time images show in mice how nerves may be damaged during the earliest stages of multiple sclerosis. The results suggest that the critical step happens when fibrinogen, a blood-clotting protein, leaks into the central nervous system and activates immune cells called microglia.

28 Nov 2012

Merrimack’s MM-302 Phase I results and MM-DX-929 preclinical data to be presented at SABCS

Merrimack Pharmaceuticals, Inc. today announced that Phase I data evaluating the novel agent MM-302 for the treatment of advanced HER2+ breast cancer and preclinical data on potential imaging and biomarker-based diagnostics will be presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), Dec. 4-8, 2012 in San Antonio, Texas.

28 Nov 2012

Rhythm raises additional $8 million to complete Series B financing

Rhythm announced today that the company has raised an additional $8 million to complete a $33 million Series B financing.

27 Nov 2012

Grove professor to investigate personalized therapies against breast cancer

For some time, researchers have known about disparities in diagnoses and outcomes among breast cancer patients based on race and age. However, they have been challenged to develop a set of criteria that can be used to reliably target drug delivery mechanisms based on an individual patient's tumor.

27 Nov 2012

Antifibrinolytics inhibit glycine receptor activity in the brain and cause seizures

Antifibrinolytic drugs are frequently used to prevent blood loss during surgery, but sometimes cause convulsive seizures. In this issue of the Journal of Clinical Investigation, researchers led by Beverly Orser at the University of Toronto investigated the molecular mechanisms that underlie this side effect.

27 Nov 2012

Paper illuminates importance of PKM2 in cancer development and progression

Researchers at The University of Texas MD Anderson Cancer Center have tracked down a cancer-promoting protein's pathway into the cell nucleus and discovered how, once there, it fires up a glucose metabolism pathway on which brain tumors thrive.

26 Nov 2012

Nonfunctional MED12 gene linked to chemotherapy resistance

Research published in Cell shows that people with tumors that have a nonfunctional version of the mediator 12 gene are resistant to drugs used to treat lung and colon cancer such as gefitinib.

26 Nov 2012

Receptor News and Research

Enzalutamide shows promise in treating triple-negative and estrogen-positive breast cancer

Vitamin D receptor polymorphism may protect against osteoporosis

Tissue damage, disease severity in C. diff. infection associated with disruption of PPARγ pathway

Study of hospital-acquired infection yields potential therapeutic target

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Fn14 gene plays a role in growth and spread of non-small cell lung cancer tumors

Modified vitamin D receptor may reduce risk of osteoporosis

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

LP-211 compound shows promise against Fragile X syndrome

Study identifies metabolic factors related to bread's beneficial effects on cardiovascular health

IL17RC-mediated immune responses can be crucial in causing AMD

ACE-inhibitors, angiotensin receptor blockers can treat heart failure with preserved ejection fraction

NovImmune commences NI-0101 Phase I clinical trial in arthritis

High-resolution real-time images show how nerves may be damaged during earliest stages of MS

Merrimack’s MM-302 Phase I results and MM-DX-929 preclinical data to be presented at SABCS

Rhythm raises additional $8 million to complete Series B financing

Grove professor to investigate personalized therapies against breast cancer

Antifibrinolytics inhibit glycine receptor activity in the brain and cause seizures

Paper illuminates importance of PKM2 in cancer development and progression

Nonfunctional MED12 gene linked to chemotherapy resistance

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News